Home・Lista de Ações・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Fechado

SetorSaúde

2.35 -4.47

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.15

Máximo

2.46

Indicadores-chave
By Trading Economics
Rendimento	14M -1M
Vendas	16M 21M
EPS	-0.003
Margem de lucro	-4.943
Funcionários	81
EBITDA	15M 657K

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+105.31% upside

Dividendos
By Acuity
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	324M 1B
Abertura anterior	6.82
Fecho anterior	2.35

Sentimento de Notícias

By Acuity

50%

156 / 340 Ranking em Healthcare

Lexicon Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de ago. de 2026, 19:36 UTC

News

Lexicon Pharmaceuticals Inc shares are lower as investors adjust positions ahead of Q2 earnings on August 5, with consensus EPS estimates at -$0.05.

4 de ago. de 2026, 19:56 UTC

Lexicon Pharmaceuticals shares are higher today, reflecting strong momentum amid easing inflation concerns from declining crude oil prices. No specific news was identified.

31 de jul. de 2026, 19:46 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reflecting broader market trends amid rising yields and crude oil prices contributing to inflation concerns.

30 de jul. de 2026, 23:11 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market hours. The decline follows broader market uncertainty after the Federal Reserve's interest rate decision.

29 de jul. de 2026, 21:02 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market declines amid rising oil prices and geopolitical tensions in the Middle East.

27 de jul. de 2026, 19:03 UTC

Lexicon Pharmaceuticals Inc is trading lower today, breaking a trend of higher daily closes. Broader market declines and falling oil prices may influence sentiment.

24 de jul. de 2026, 20:07 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reversing from earlier gains amid broader market volatility influenced by falling oil prices and inflation concerns.

22 de jul. de 2026, 19:02 UTC

Lexicon Pharmaceuticals Inc shares are lower today, continuing a decline since Tuesday's close. The stock remains below its 20-day moving average.

21 de jul. de 2026, 19:42 UTC

Lexicon Pharmaceuticals is higher as the market gains momentum, driven by strong performances from major companies and a resurgence in semiconductor stocks.

20 de jul. de 2026, 19:06 UTC

Lexicon Pharmaceuticals Inc shares are lower today, following three days of gains. Broader market declines are linked to rising US Treasury yields and oil prices above $90.

Comparação entre Pares

Variação de preço

Lexicon Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

105.31% parte superior

Previsão para 12 meses

Média 5.03 USD 105.31%

Máximo 6 USD

Mínimo 3.1 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Lexicon Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

Comprar

Manter

Vender

Com base em 3 analistas que deram avaliações de ações para Lexicon Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

156 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.